Barclays PLC Buys 32,784 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Barclays PLC lifted its stake in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 323.0% in the third quarter, Holdings Channel.com reports. The fund owned 42,935 shares of the company’s stock after acquiring an additional 32,784 shares during the quarter. Barclays PLC’s holdings in Actinium Pharmaceuticals were worth $81,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ATNM. Bank of New York Mellon Corp increased its position in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after purchasing an additional 19,035 shares during the period. Rhumbline Advisers boosted its stake in shares of Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth $142,000. Marshall Wace LLP raised its stake in Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after buying an additional 103,557 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Actinium Pharmaceuticals in the second quarter valued at $356,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Down 5.8 %

Shares of Actinium Pharmaceuticals stock opened at $1.31 on Friday. The firm has a market capitalization of $40.87 million, a PE ratio of -0.94 and a beta of 0.12. Actinium Pharmaceuticals, Inc. has a 52 week low of $1.10 and a 52 week high of $10.24. The firm has a 50 day moving average price of $1.43.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ATNM shares. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Stephens reaffirmed an “overweight” rating and set a $5.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).